Showing results (1-10 of 78) with videos related to
Sort By:
Pageof 8
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|March 5, 2008
The Role of PPARgamma in pulmonary vascular diseaseC Michael HartJournal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|July 27, 2005
Alcohol abuse and acute lung injury: epidemiology and pathophysiology of a recently recognized associationDavid M Guidot, C Michael HartLung|October 3, 2007
The peroxisome proliferator activated receptor gamma (PPARgamma) ligand rosiglitazone modulates bronchoalveolar lavage levels of leptin, adiponectin, and inflammatory cytokines in lean and obese miceFernando Holguin, Mauricio Rojas, C Michael HartCancer Therapy|December 17, 2008
Thiazolidinediones as anti-cancer agentsCarmelo Blanquicett, Jesse Roman, C Michael HartSouthern Medical Journal|November 12, 2002
Enterococcus faecalis causing empyema in a patient with liver diseaseMehrdad Behnia, Alison S Clay, C Michael HartAntioxidants & Redox Signaling|December 25, 2018
Redox Biology of Peroxisome Proliferator-Activated Receptor-γ in Pulmonary HypertensionVictor Tseng, Roy L Sutliff, C Michael HartHealth Equity|June 7, 2023
The Atlanta VA Health Care System: Morehouse School of Medicine Core Recruiting Site-A Strategy to Increase Diversity in the VA Scientific WorkforceC Michael Hart, Kennie R Shepherd, Walter RoyalTherapeutic Advances in Respiratory Disease|June 10, 2010
PPARgamma as a potential therapeutic target in pulmonary hypertensionRoy L Sutliff, Bum-Yong Kang, C Michael HartPPAR Research|August 22, 2007
The role of peroxisome proliferator-activated receptors in pulmonary vascular diseaseRachel E Nisbet, Roy L Sutliff, C Michael HartPulmonary Circulation|May 7, 2011
Is peroxisome proliferator-activated receptor gamma (PPARγ) a therapeutic target for the treatment of pulmonary hypertension?David E Green, Roy L Sutliff, C Michael HartPageof 8